Baghel Uttam Singh, Kriplani Priyanka, Patel Neelam M, Kaur Manpreet, Sharma Kapil, Meghani Monika, Sharma Abhay, Singh Deeksha, Singh Bhawani, Setzer William N, Sharifi-Rad Javad, Calina Daniela
Gurukul Pharmacy College, Ranpur, 325003, Kota, India.
Guru Gobind Singh College of Pharmacy, Yamuna Nagar, 135001, India.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3489-3511. doi: 10.1007/s00210-024-03599-2. Epub 2024 Nov 26.
Flavopiridol, a synthetic flavonoid derived from rohitukine, stands out as a powerful cyclin-dependent kinase (CDK) inhibitor with significant anticancer properties. Its action mechanisms involve inducing cell cycle arrest, triggering apoptosis, and inhibiting transcription across various cancer types. Despite these promising effects, flavopiridol's clinical use has been hampered by issues related to toxicity and drug resistance. This study aims to comprehensively review flavopiridol's mechanisms of action, structure-activity relationships, synthetic derivatives, pharmacokinetics, and its potential role in clinical applications, with a focus on how combination therapies can enhance its efficacy and address resistance challenges in cancer treatment. A thorough analysis of key studies was performed, examining flavopiridol's anticancer properties, emphasizing its structure-activity relationships, synthetic modifications, and clinical outcomes. The anticancer effects of flavopiridol are primarily driven by its inhibition of CDKs, induction of apoptosis, promotion of oxidative stress, and antiangiogenic activity. Modifications in its chemical structure, especially in the D ring, have shown a significant impact on its CDK inhibitory potency. Several synthetic derivatives have also demonstrated enhanced anticancer activity. While preclinical models highlight flavopiridol's potential in treating cancers such as leukemia and solid tumors, clinical trials have brought attention to its limitations, particularly regarding toxicity and resistance. However, flavopiridol remains a promising candidate for cancer therapy, especially when used in combination with other treatments. Future research efforts should focus on refining its therapeutic profile, minimizing toxicity, and investigating synergistic treatment combinations, including those with immunotherapy. Understanding the mechanisms of resistance and discovering predictive biomarkers will be crucial for its effective integration into clinical practice.
黄酮哌啶醇是一种从罗西土碱衍生而来的合成类黄酮,是一种具有显著抗癌特性的强大细胞周期蛋白依赖性激酶(CDK)抑制剂。其作用机制包括诱导细胞周期停滞、触发细胞凋亡以及抑制多种癌症类型的转录。尽管有这些令人期待的效果,但黄酮哌啶醇的临床应用因毒性和耐药性问题而受到阻碍。本研究旨在全面综述黄酮哌啶醇的作用机制、构效关系、合成衍生物、药代动力学及其在临床应用中的潜在作用,重点关注联合疗法如何提高其疗效并应对癌症治疗中的耐药挑战。对关键研究进行了深入分析,考察黄酮哌啶醇的抗癌特性,强调其构效关系、合成修饰及临床结果。黄酮哌啶醇的抗癌作用主要由其对CDK的抑制、细胞凋亡的诱导、氧化应激的促进及抗血管生成活性驱动。其化学结构的修饰,尤其是D环的修饰,对其CDK抑制效力有显著影响。几种合成衍生物也显示出增强的抗癌活性。虽然临床前模型突出了黄酮哌啶醇在治疗白血病和实体瘤等癌症方面的潜力,但临床试验也关注到了其局限性,特别是在毒性和耐药性方面。然而,黄酮哌啶醇仍是癌症治疗的一个有前景的候选药物,尤其是与其他治疗联合使用时。未来的研究应致力于优化其治疗特性、降低毒性,并研究协同治疗组合,包括与免疫疗法的组合。了解耐药机制并发现预测性生物标志物对于其有效融入临床实践至关重要。